PHATHOM PHARMACEUTICAL

Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement

01 11 2022 08:00:02 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)

24 10 2022 08:00:02 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

23 10 2022 12:01:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting

18 10 2022 08:00:02 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

26 9 2022 08:00:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

07 9 2022 08:15:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates

02 8 2022 11:48:42 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference

01 6 2022 08:15:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis

25 5 2022 08:00:01 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022

24 5 2022 12:15:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting

17 5 2022 08:01:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates

10 5 2022 08:00:01 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital

04 5 2022 08:01:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

03 5 2022 17:40:31 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors

26 4 2022 08:00:01 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

01 4 2022 08:01:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

22 3 2022 08:02:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress

01 3 2022 16:04:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)

09 2 2022 16:04:00 提供 Nasdaq GlobeNewswire

Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Conference

23 11 2021 16:00:00 提供 Nasdaq GlobeNewswire